Wild-type IL-2 drives strong anti-tumor responses but causes severe toxicity, including cytokine release syndrome (CRS), vascular leak syndrome (VLS), and expansion of regulatory T cells (Tregs), which limit its clinical use. IL-10 can suppress both CRS and Treg expansion. Researchers developed a fusion of IL-2 with a modified IL-10, which maintains T and NK cell activation while reducing toxicity. Targeting this fusion molecule (DK210-EGFR) to tumors via an anti-EGFR fragment further enhances its potency. This approach uncouples IL-2’s toxicity from its therapeutic effects, offering a safer and more effective cancer immunotherapy strategy.
More Readings
Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity
SHARE
